Cogent Biosciences Inc (NAS:COGT)

$ 10.21 0.16 (1.59%) Market Cap: 1.12 Bil Enterprise Value: 869.07 Mil PE Ratio: 0 PB Ratio: 4.24 GF Score: 36/100

Cogent Biosciences Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2024
Cogent Biosciences Inc to Host ASH Investor Event Transcript
Dec 11, 2023
Cogent Biosciences Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2023
Cogent Biosciences Inc at Jefferies Healthcare Conference Transcript
Jun 08, 2023
Cogent Biosciences Inc To Discuss Lead-In GIST Data at ASCO from the Ongoing PEAK Phase 3 Trial Evaluating Bezuclastinib in Combination with Sunitinib Call Transcript
Jun 05, 2023
Cogent Biosciences Inc at Stifel Targeted Oncology Days (Virtual) Transcript
Apr 25, 2023
Cogent Biosciences Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 19, 2023
Cogent Biosciences Inc at JPMorgan Healthcare Conference Transcript
Jan 12, 2023
Cogent Biosciences Inc To Discuss Updated APEX Trial Phase 2 Data at ASH Call Transcript
Dec 12, 2022
Cogent Biosciences Inc To Discuss Initial Clinical Data presented At the European Hematology Association Congress Call Transcript
Jun 10, 2022
Cogent Biosciences Inc To Host An R&D Investor Event Transcript
Apr 08, 2022
Cogent Biosciences Inc at Ladenburg Thalmann Virtual Healthcare Conference Transcript
Jul 14, 2021
Kiq LLC, Unum Therapeutics Inc. - M&A Call Transcript
Jul 06, 2020
Unum Therapeutics Inc. - Special Call Transcript
Nov 04, 2019
Unum Therapeutics Inc at Morgan Stanley Healthcare Conference Transcript
Sep 09, 2019
Q2 2019 Unum Therapeutics Inc Earnings Call Transcript
Aug 12, 2019

$7.16 (-2.19%)

Earnings
Q1 2019 Unum Therapeutics Inc Earnings Call Transcript
May 13, 2019

$12.84 (-6.41%)

Earnings
Q4 2018 Unum Therapeutics Inc Earnings Call Transcript
Mar 28, 2019

$17.64 (+8.62%)

Earnings

Cogent Biosciences Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2023 / 12:10PM GMT

Release Date Price: $11.5 (-5.58%)

Transcript

Jason Russell

Morgan Stanley - MD

Good morning, everyone. Welcome to the third and final day of the Morgan Stanley Healthcare Conference. Thanks, everyone, for attending.

My name is Jason Russell with the Healthcare Investment Banking team at Morgan Stanley. Before I jump in and introduce Andy, a quick research disclosure. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/research disclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

So briefly, on stage here with Andy Robbins, President and CEO of Cogent. Cogent is a clinical-stage company focused on developing precision therapies for genetically-defined diseases. Most advanced clinical program is bezuclastinib. I'm going to try and pronounce that correctly, which is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation, as well as other KIT exon 17 mutations.

Bezu is being studied in systemic

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.